BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Intarcia Therapeutics, Inc. 

155 Seaport Boulevard
11th Floor
Boston  Massachusetts  02210  U.S.A.
Phone: 617-936-2500 Fax: n/a


SEARCH JOBS

View Clinical Trials from BioPharm Insight



Industry
Pharmaceutical

Segment
Drug Discovery





 Company News
Servier Bets $1 Billion+ On Intarcia Therapeutics, Inc.'s Diabetes Device 11/12/2014 6:12:53 AM
Boston's Intarcia Therapeutics, Inc. Touts Trial Results Of Potentially Revolutionary Type 2 Diabetes Treatment 10/2/2014 6:39:08 AM
Intarcia Therapeutics, Inc. Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 9/17/2014 8:58:43 AM
Intarcia Therapeutics, Inc. Announces Two Presentations At 50th EASD Meeting: Confirms Pivotal Phase 3 Data Announcement For ITCA 650 In Type 2 Diabetes In 4Q 9/12/2014 9:00:59 AM
Intarcia Therapeutics, Inc. Announces Appointment Of Dr. Sunita Zalani As Vice President, Global Head Of Regulatory Affairs And Quality 8/5/2014 9:26:37 AM
Intarcia Therapeutics, Inc. Release: Chairman & CEO Kurt Graves Presents First "Key Disruptor Award" To Tom Alessi, Ph.D., For His Innovations In Chemistry And Manufacturing That Transform Medicines For Patients 6/19/2014 10:02:27 AM
Intarcia Therapeutics, Inc.'s Once-A-Year Diabetes Drug ITCA 650 Impresses In Phase 3 Trial 6/16/2014 7:06:24 AM
Intarcia Therapeutics, Inc. Presents Interim Phase 3 Data At American Diabetes Association Showing ITCA 650, A Once Yearly GLP-1, Markedly Reduces Blood Sugar In Patients With Very Poorly Controlled Diabetes 6/16/2014 6:29:50 AM
Boston-Based Intarcia Therapeutics, Inc. Grabs $200 Million To Beef Up Pipeline 4/1/2014 7:24:14 AM
Intarcia Therapeutics, Inc. CEO To Present Company Progress, Interim Phase 3 Data, And Key Milestones At J.P. Morgan 1/13/2014 8:41:33 AM
123456